|
1
|
Cheung-Ong K, Giaever G and Nislow C:
DNA-damaging agents in cancer chemotherapy: Serendipity and
chemical biology. Chem Biol. 20:648–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lord CJ and Ashworth A: The DNA damage
response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bouwman P and Jonkers J: The effects of
deregulated DNA damage signaling on cancer chemotherapy response
and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luo Y and Leverson JD: New opportunities
in chemosensitization and radiosensitization: Modulating the
DNA-damage response. Expert Rev Anticancer Ther. 5:333–342. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–727. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou BB and Bartek J: Targeting the
checkpoint kinases: Chemosensitization versus chemoprotection. Nat
Rev Cancer. 4:216–225. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gu P, Min JN, Wang Y, Huang C, Peng T,
Chai W and Chang S: CTC1 deletion results in defective telomere
replication, leading to catastrophic telomere loss and stem cell
exhaustion. EMBO J. 31:2309–2321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang C, Dai X and Chai W: Human Stn1
protects telomere integrity by promoting efficient lagging-strand
synthesis at telomeres and mediating C-strand fill-in. Cell Res.
22:1681–1695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stewart JA, Wang F, Chaiken MF, Kasbek C,
Chastain PD II, Wright WE and Price CM: Human CST promotes telomere
duplex replication and general replication restart after fork
stalling. EMBO J. 31:3537–3549. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Casteel DE, Zhuang S, Zeng Y, Perrino FW,
Boss GR, Goulian M and Pilz RB: A DNA polymerase-{alpha}{middle
dot}primase cofactor with homology to replication protein A-32
regulates DNA replication in mammalian cells. J Biol Chem.
284:5807–5818. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wan M, Qin J, Songyang Z and Liu D:
OB-fold containing protein 1 (OBFC1), a human homolog of yeast
Stn1, associates with TPP1 and is implicated in telomere length
regulation. J Biol Chem. 284:26725–26731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen LY, Majerská J and Lingner J:
Molecular basis of telomere syndrome caused by CTC1 mutations.
Genes Dev. 27:2099–2108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anderson BH, Kasher PR, Mayer J,
Szynkiewicz M, Jenkinson EM, Bhaskar SS, Urquhart JE, Daly SB,
Dickerson JE, O'Sullivan J, et al: Mutations in CTC1, encoding
conserved telomere maintenance component 1, cause Coats plus. Nat
Genet. 44:338–342. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen LY, Redon S and Lingner J: The human
CST complex is a terminator of telomerase activity. Nature.
488:540–544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang F, Stewart JA, Kasbek C, Zhao Y,
Wright WE and Price CM: Human CST has independent functions during
telomere duplex replication and C-strand fill-in. Cell Rep.
2:1096–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu P, Takai H and de Lange T: Telomeric 3′
overhangs derive from resection by Exo1 and Apollo and fill-in by
POT1b-associated CST. Cell. 150:39–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shay JW and Wright WE: Telomerase
therapeutics for cancer: Challenges and new directions. Nat Rev
Drug Discov. 5:577–584. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Cian A, Lacroix L, Douarre C,
Temime-Smaali N, Trentesaux C, Riou JF and Mergny JL: Targeting
telomeres and telomerase. Biochimie. 90:131–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mondello C and Scovassi IA: Telomeres,
telomerase, and apoptosis. Biochem Cell Biol. 82:498–507. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan SR and Blackburn EH: Telomeres and
telomerase. Philos Trans R Soc Lond B Biol Sci. 359:109–121. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Bohr VA and Lansdorp P: Telomere,
telomerase and aging. Mech Ageing Dev. 129:1–2. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen M and McLeskey SW: Telomere-based
cancer treatment: emerging targeted therapies. Clin J Oncol
Nursing. 14:720–727. 2010. View Article : Google Scholar
|
|
24
|
Herbert BS, Gellert GC, Hochreiter A,
Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW and
Gryaznov SM: Lipid modification of GRN163, an N3′-P5′
thio-phosphoramidate oligonucleotide, enhances the potency of
telomerase inhibition. Oncogene. 24:5262–5268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dai X, Huang C, Bhusari A, Sampathi S,
Schubert K and Chai W: Molecular steps of G-overhang generation at
human telomeres and its function in chromosome end protection. EMBO
J. 29:2788–2801. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Collins AR: The comet assay. Principles,
applications, and limitations. Methods Mol Biol. 203:163–177.
2002.PubMed/NCBI
|
|
27
|
Gu P and Chang S: Functional
characterization of human CTC1 mutations reveals novel mechanisms
responsible for the pathogenesis of the telomere disease Coats
plus. Aging Cell. 12:1100–1109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pizarro JG, Folch J, Junyent F, Verdaguer
E, Auladell C, Beas-Zarate C, Pallàs M and Camins A: Antiapoptotic
effects of roscovitine on camptothecin-induced DNA damage in
neuroblastoma cells. Apoptosis. 16:536–550. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berniak K, Rybak P, Bernas T, Zarębski M,
Biela E, Zhao H, Darzynkiewicz Z and Dobrucki JW: Relationship
between DNA damage response, initiated by camptothecin or oxidative
stress, and DNA replication, analyzed by quantitative 3D image
analysis. Cytometry A. 83:913–924. 2013.PubMed/NCBI
|
|
30
|
Nguyen TV, Chen JK and Murray V: Bleomycin
DNA damage: Anomalous mobility of 3′-phosphoglycolate termini in an
automated capillary DNA sequencer. J Chromatogr B Analyt Technol
Biomed Life Sci. 913–914:113–122. 2013. View Article : Google Scholar
|
|
31
|
Patel JR, Dhorajiya BD, Dholakiya BZ,
Badria FA and Ibrahim AS: In-vitro cytotoxicity, antioxidant,
bleomycin-dependent DNA damage and immunomodulatory evaluation of
1-(4-acetylphenyl)-3-aryloxypyrrolidine-2, 5-dione based
derivatives. Med Chem Res. 23:3907–3915. 2014. View Article : Google Scholar
|
|
32
|
Li X, Liu W, Wang H, Yang L, Li Y, Wen H,
Ning H, Wang J, Zhang L, Li J and Fan D: Rap1 is indispensable for
TRF2 function in etoposide-induced DNA damage response in gastric
cancer cell line. Oncogenesis. 4:e1442015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Griaud F, Williamson AJK, Taylor S, Potier
DN, Spooncer E, Pierce A and Whetton AD: BCR/ABL modulates protein
phosphorylation associated with the etoposide-induced DNA damage
response. J Proteomics. 77:14–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grand CL, Han H, Muñoz RM, Weitman S, Von
Hoff DD, Hurley LH and Bearss DJ: The cationic porphyrin TMPyP4
down-regulates c-MYC and human telomerase reverse transcriptase
expression and inhibits tumor growth in vivo. Mol Cancer
Ther. 1:565–573. 2002.PubMed/NCBI
|
|
35
|
Tarsounas M and Tijsterman M: Genomes and
G-quadruplexes: For better or for worse. J Mol Biol. 425:4782–4789.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bochman ML, Paeschke K and Zakian VA: DNA
secondary structures: Stability and function of G-quadruplex
structures. Nat Rev Genet. 13:770–780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Borowicz S, Scoyk MV, Avasarala S,
Rathinam Karuppusamy MK, Tauler J, Bikkavilli RK and Winn RA: The
soft agar colony formation assay. J Vis Exp.
92:e519982014.PubMed/NCBI
|
|
38
|
Horibata S, Vo TV, Subramanian V, Thompson
PR and Coonrod SA: Utilization of the soft agar colony formation
assay to identify inhibitors of tumorigenicity in breast cancer
cells. J Vis Exp. 99:e527272015.PubMed/NCBI
|
|
39
|
IARC/NCI/EPA Working Group: Cellular and
molecular mechanisms of cell transformation and standardization of
transformation assays of established cell lines for the prediction
of carcinogenic chemicals: Overview and recommended protocols.
Cancer Res. 45:2395–2399. 1985.
|
|
40
|
Kolber AR, Wong TK, Grant LD, DeWoskin RS
and Hughes TJ: In Vitro Toxicity Testing of Environmental Agents.
Current and Future Possibilities Part A: Survey of Test Systems.
Plenum Press. (New York). 321–322. 1979.
|
|
41
|
Pullman B, Ts'O POP and Schneider EL:
Interrelationship Among Aging, Cancer and Differentiation. The
Jerusalem Symposia on Quantum Chemistry and Biochemistry. 18:D.
Reidel Publishing Company. (Dordrecht, The Netherlands). 247–248.
1985.
|
|
42
|
Collins AR: The comet assay for DNA damage
and repair: Principles, applications, and limitations. Mol
Biotechnol. 26:249–261. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hosoya N and Miyagawa K: Targeting DNA
damage response in cancer therapy. Cancer Sci. 105:370–388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dickerson EB, Blackburn WH, Smith MH, Kapa
LB, Lyon LA and McDonald JF: Chemosensitization of cancer cells by
siRNA using targeted nanogel delivery. BMC Cancer. 10:102010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang F, Stewart J and Price CM: Human CST
abundance determines recovery from diverse forms of DNA damage and
replication stress. Cell Cycle. 13:3488–3498. 2014. View Article : Google Scholar : PubMed/NCBI
|
